Last Updated : April 16, 2025
Details
Generic Name:
empagliflozin
Project Status:
Not filed
Therapeutic Area:
Chronic kidney disease
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Brand Name:
Jardiance
Project Line:
Reimbursement Review
Project Number:
NS0040-000
Biosimilar:
No
Fee Schedule:
N/A
Indications:
Reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular and renal death in adults with chronic kidney disease.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : April 16, 2025